期刊
TRANSFUSION MEDICINE AND HEMOTHERAPY
卷 40, 期 6, 页码 388-402出版社
KARGER
DOI: 10.1159/000357163
关键词
Adoptive cell transfer; Chimeric antigen receptor; CAR; T-cell receptor; TCR; Clinical trial
The broaden application of adoptive T-cell transfer has been constrained by the technical abilities to isolate and expand antigen-specific T cells potent to selectively kill tumor cells. With the recent progress in the design and manufacturing of cellular products, T cells used in the treatment of malignant diseases may be regarded as anticancer biopharmaceuticals. Genetical manipulation of T cells has given T cells desired specificity but also enable to tailor their activation and proliferation potential. Here, we summarize the recent developments in genetic engineering of T-cell-based biopharmaceuticals, covering criteria for their clinical application in regard to safety and efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据